MK 8504

Drug Profile

MK 8504

Alternative Names: MK-8504

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antiretrovirals
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV-1 infections

Most Recent Events

  • 08 Sep 2017 Phase-I clinical trials in HIV-1 infections (Treatment-naive, Monotherapy) in Germany (PO) (NCT03188523)
  • 23 Jun 2017 Preclinical trials in HIV-1 infections in Germany (PO) (NCT03188523) before June 2017
  • 14 Jun 2017 Merck Sharp & Dohme plans a phase I trial for HIV-1 Infection (Treatment-naive, Monotherapy) (NCT03188523)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top